INTERNATIONAL MULTI DISCIPLINARY JOURNAL FOR RESEARCH & DEVELOPMENT
eISSN 2394-6334 Impact factor: 8.854 Volume 13, issue 01 (2026)

UDC: 616.921.5-07:616.2-002-079.4

DIFFERENTIAL DIAGNOSIS OF ACUTE RESPIRATORY VIRAL INFECTIONS AND INFLUENZA BASED ON CLINICAL SYMPTOMS: A COMPARATIVE ANALYSIS

Solomonnik Oksana Nikolaevna
Department of infectious diseases Andijan State Medical Institute, Uzbekistan, Andijan

Abstract

Background: Acute Respiratory Viral Infections (ARVI) and Influenza share similar transmission routes and overlapping symptoms, yet they differ significantly in prognosis and management. Misdiagnosis often leads to inappropriate antibiotic use and failure to prescribe specific antivirals for influenza. This study aims to identify the key clinical discriminators between seasonal Influenza and non-influenza ARVI to improve bedside diagnostic accuracy in primary care settings. Methods: A prospective observational study was conducted involving 400 patients presenting with acute respiratory symptoms during the epidemic season. Patients were stratified into two groups based on PCR confirmation: Group 1 (Influenza A/B, n=150) and Group 2 (Non-Influenza ARVI, n=250). Clinical parameters including onset speed, fever magnitude, intoxication signs, and catarrhal symptoms were compared. Results: Influenza was characterized by a hyperacute onset (92% vs 15% in ARVI, $p<0.001$), high fever >38.5°C (88% vs 22%), and severe systemic intoxication (myalgia, headache) with minimal initial catarrhal symptoms. In contrast, non-influenza ARVI presented with a gradual onset, predominant rhinorrhea, and sneezing. The combination of "Sudden onset + Fever >38°C + Cough + Absence of Runny Nose" had a positive predictive value of 85% for Influenza. Conclusion: While laboratory confirmation is the gold standard, specific clinical constellations allow for reliable early differentiation. Recognizing the "Intoxication-Catarrhal Dissociation" is crucial for the timely administration of neuraminidase inhibitors and the reduction of unnecessary antibiotic prescriptions.

Keywords

Influenza, ARVI, differential diagnosis, clinical symptoms, intoxication syndrome, catarrhal syndrome, primary care.

INTRODUCTION

Acute respiratory infections (ARIs) represent a massive burden on global healthcare systems, constituting the primary reason for outpatient visits and antibiotic prescriptions. Within this broad nosological group, the clinical landscape is dominated by a diverse array of pathogens, including Influenza viruses (A and B), Rhinoviruses, Adenoviruses, Coronaviruses, Parainfluenza viruses, and Respiratory Syncytial Virus (RSV). While often colloquially grouped under the umbrella term "common cold" or "flu," Influenza and other Acute Respiratory Viral Infections (ARVI) are distinct clinical entities with divergent pathophysiologies, complication profiles, and management strategies.

Influenza, in particular, carries a significant risk of severe morbidity and mortality, especially in vulnerable populations such as the elderly, young children, and those with chronic comorbidities. Complications range from primary viral pneumonia and myocarditis to secondary bacterial superinfections leading to sepsis. Conversely, non-influenza ARVIs are generally self-limiting, causing significant economic loss due to absenteeism but rarely threatening life in immunocompetent adults.

In the resource-constrained primary care settings of the Andijan region and wider Uzbekistan, the "Gold Standard" diagnostic tools—such as Polymerase Chain Reaction (PCR) or rapid antigen detection tests (RIDTs)—are not universally accessible for every patient presenting with fever and cough. Even when available, the cost and turnaround time can be prohibitive for immediate decision-making. Consequently, General Practitioners (GPs) and infectious disease specialists are forced to rely heavily on clinical acumen and symptom-based diagnosis to triage patients.

This reliance on clinical judgment creates a critical diagnostic dilemma. The misdiagnosis of Influenza as a benign ARVI results in the missed opportunity to prescribe specific neuraminidase inhibitors (e.g., Oseltamivir), which are only effective if initiated within the first 48 hours of symptom onset. On the other hand, the misdiagnosis of a viral ARVI as a bacterial infection or "severe flu" drives the rampant and inappropriate overuse of antibiotics, accelerating the global crisis of antimicrobial resistance (AMR). Therefore, refining the "art of clinical diagnosis" through rigorous statistical validation of symptom clusters is not merely an academic exercise but a public health necessity. This study aims to delineate the specific clinical phenotypes that reliably differentiate Influenza from other ARVIs, empowering local practitioners to make evidence-based decisions at the bedside.

LITERATURE REVIEW

Pathophysiology - Systemic Toxicity vs. Local Inflammation The clinical divergence between Influenza and ARVI is rooted in their distinct pathogenic mechanisms. Influenza viruses possess a unique tropism for the tracheobronchial epithelium. Upon infection, they replicate rapidly, causing massive cytolysis and triggering a potent systemic immune response characterized by a "cytokine storm" (elevated levels of Interferon-alpha, TNF-alpha, and IL-6). This systemic viremia-like state manifests clinically as severe intoxication—high fever, debilitating myalgia, and arthralgia—often preceding significant local respiratory symptoms. In contrast, agents like Rhinoviruses replicate primarily in the cooler environment of the nasopharynx. Their pathogenicity is driven by the local release of bradykinin and histamine, leading to vasodilation and mucus hypersecretion. Thus, the clinical picture is dominated by "wet" symptoms (rhinorrhea, congestion, sneezing) with minimal systemic spillover.

The Challenge of Symptom Overlap Despite these theoretical differences, "textbook" presentations are not universal. *Call et al. (2005)* conducted a landmark meta-analysis showing that individual symptoms have poor sensitivity. For instance, fever is absent in up to 30% of elderly influenza patients. Conversely, Adenovirus infections can mimic the high fever of influenza but are often accompanied by conjunctivitis ("pharyngoconjunctival fever"), a sign rarely seen in the flu. The overlap is further complicated by the circulation of COVID-19, which shares features of both (loss of smell, fever, cough), although this study focuses on the classic pre-pandemic differential.

Clinical Prediction Rules Various attempts have been made to create scoring systems. The "Fever + Cough" rule is widely cited, having a positive predictive value (PPV) of nearly 80% during peak influenza season. However, its specificity drops dramatically when other viruses like RSV or Parainfluenza are co-circulating. *Ebell et al. (2012)* emphasized that the onset of symptoms—specifically the *speed* of deterioration—is a critical but often under-documented discriminator.

Antibiotic Stewardship Implications The inability to confidently rule out bacterial co-infection or severe influenza leads to "defensive medicine." Studies indicate that over 50% of patients with uncomplicated ARVI receive antibiotics. Improving clinical diagnostic confidence is the most direct way to curb this malpractice. There is a need for local data validating these

clinical signs in the specific population of the Fergana Valley, where cultural perceptions of illness (e.g., "fear of cold") influence symptom reporting.

MATERIALS AND METHODS

Study Design A prospective observational study was conducted at the Andijan Regional Infectious Diseases Hospital and two district family polyclinics during the autumn-winter season (November 2023 – February 2024).

Participants 400 patients (aged 18–65) presenting with acute respiratory symptoms (<72 hours duration) were included. Gold Standard: All patients underwent nasopharyngeal swabbing for Real-Time PCR to detect Influenza A/B, SARS-CoV-2, and other respiratory viruses.

Grouping - Based on PCR results, patients were divided into - Group 1 (Influenza): 150 patients. Group 2 (Non-Influenza ARVI) - 250 patients (Rhinovirus, Adenovirus, Parainfluenza). Note - COVID-19 positive patients were excluded to focus on the classic Flu vs. ARVI dilemma.

Clinical Assessment A standardized checklist was used to record: Onset - Sudden (within hours) vs. Gradual (over days). Temperature: Peak value and duration. Intoxication- Headache, myalgia (muscle pain), ocular pain (retro-orbital), fatigue. Catarrhal Signs - Rhinorrhea (runny nose), sneezing, sore throat, cough type (dry/wet).

Statistical Analysis Sensitivity, Specificity, and Positive Predictive Value (PPV) were calculated for individual symptoms and symptom clusters using SPSS v26.

RESULTS

Onset and Fever The mode of onset was the most discriminatory feature.

Influenza: 92% reported a "lightning-fast" onset (feeling well in the morning, bedridden by evening). 88% had fever >38.5°C.

ARVI: 85% reported a gradual onset (prodromal scratchy throat, then runny nose, then mild fever). Fever remained <38.0°C in 78% of cases.

The "Intoxication-Catarrhal" Balance This study identified a distinct dissociation in symptoms.

Table 1: Frequency of Clinical Symptoms (%)

Symptom	Group 1 (Influenza)	Group 2 (ARVI)	P-value
Severe Headache	85.3%	15.2%	<0.001
Retro-orbital Pain (Eye pain)	62.0%	4.0%	<0.001
Myalgia/Arthralgia	90.0%	12.0%	<0.001
Profuse Rhinorrhea (Runny nose)	18.0%	95.0%	<0.001
Sneezing	10.0%	88.0%	<0.001
Dry, Hacking Cough	94.0%	40.0%	<0.001

Diagnostic Accuracy The cluster of "Sudden Onset + Fever >38°C + Cough" had a Sensitivity of 82% and Specificity of 75% for Influenza. Adding "Absence of early rhinorrhea" increased Specificity to 92%. Conversely, "Sneezing + Nasal Congestion + Normal/Low Fever" was 96% predictive of Non-Influenza ARVI.

DISCUSSION

The results provide a clear and actionable roadmap for differential diagnosis in the absence of immediate PCR capabilities. The study confirms that while symptoms overlap, the *constellation* and *chronology* of symptoms are distinct.

The "Face" of Influenza: It is primarily a systemic toxicosis. The patient looks "toxic"—flushed face, injected sclera (red eyes), and is often immobile due to muscle pain. The cough is usually tracheal (painful, dry, retrosternal) appearing on day 2. Crucially, the nose is often "dry" or blocked in the first 48 hours; profuse runny nose is *rare* at the onset of flu. This "dry catarrh" is a key discriminator.

The "Face" of ARVI - It is primarily a local inflammation. The patient is mobile, often continuing to work or study despite the discomfort ("walking patient"). The dominant feature is the "wet" nose (rhinorrhea) and frequent sneezing. Systemic toxicity is mild or absent; if headache is present, it is usually related to sinus congestion rather than systemic cytokines.

Retro-orbital Pain - Our data highlights pain on eye movement as a highly specific marker for Influenza (62% vs 4%). This is likely due to viral myositis of the extraocular muscles and is almost non-existent in common colds.

Clinical Implication - The identification of the "Intoxication-Catarrhal Dissociation" (high intoxication, low catarrh) should trigger immediate isolation and consideration of antiviral therapy. Conversely, "Catarrhal-Intoxication Dissociation" (high catarrh, low intoxication) should reassure the clinician to withhold antibiotics and manage symptomatically.

CONCLUSION

While laboratory tests remain the definitive gold standard, clinical acumen based on pattern recognition is a powerful, cost-effective, and immediate tool for triage in infectious disease practice.

Influenza hits with a "hyperacute" onset, incapacitating the patient within hours, whereas ARVI creeps in gradually over days.

In Influenza, the syndrome of intoxication (fever, ache) dominates over catarrhal signs. In ARVI, catarrhal signs (runny nose, sneeze) dominate over intoxication.

Severe headache, retro-orbital pain, and a dry, painful cough in the absence of a runny nose are strong indicators of Influenza.

RECOMMENDATIONS

To improve the management of acute respiratory infections in the Andijan region, we propose the following:

1. For General Practitioners:

Adopt the Algorithm: Utilize the "Intoxication vs. Catarrhal" balance to guide therapy. If a patient has a runny nose and low fever, do not prescribe antibiotics; explain the viral nature of the "cold."

Targeted Testing: Prioritize PCR testing for patients fitting the "Flu Profile" (Sudden fever + cough + no runny nose) to initiate Oseltamivir within the effective window.

Stop "Just in Case" Antibiotics: Antibiotics should be strictly reserved for confirmed bacterial superinfections (e.g., purulent sputum, otitis media, radiographic pneumonia).

2. For Public Health Policy:

Education - Launch public awareness campaigns explaining the difference between "Flu" and "Cold" to reduce patient demand for antibiotics for simple runny noses.

Triage Training - Train triage nurses in polyclinics to recognize the "toxic" appearance of flu patients for rapid isolation to prevent waiting-room transmission.

References

1. Call, S. A., et al. (2005). Does this patient have influenza? *JAMA*, 293(8), 987-997.
2. Ebell, M. H., et al. (2012). Clinical diagnosis of influenza: a systematic review. *American Family Physician*.
3. Eccles, R. (2005). Understanding the symptoms of the common cold and influenza. *The Lancet Infectious Diseases*.
4. World Health Organization. (2018). *Global Influenza Strategy 2019-2030*. WHO Press.
5. Uyeki, T. M., et al. (2019). Clinical Practice Guidelines by the IDSA: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenza. *Clinical Infectious Diseases*.